- Home
- EVRI vs SNDX Comparison
EVRI vs SNDX Comparison
Compare EVRI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVRI
- SNDX
- Stock Information
- Founded
- EVRI 1998
- SNDX 2005
- Country
- EVRI United States
- SNDX United States
- Employees
- EVRI N/A
- SNDX N/A
- Industry
- EVRI Services-Misc. Amusement & Recreation
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- EVRI Consumer Discretionary
- SNDX Health Care
- Exchange
- EVRI Nasdaq
- SNDX Nasdaq
- Market Cap
- EVRI 1.2B
- SNDX 1.1B
- IPO Year
- EVRI 2005
- SNDX 2016
- Fundamental
- Price
- EVRI N/A
- SNDX $9.00
- Analyst Decision
- EVRI Hold
- SNDX Strong Buy
- Analyst Count
- EVRI 4
- SNDX 10
- Target Price
- EVRI $12.83
- SNDX $35.80
- AVG Volume (30 Days)
- EVRI 1.4M
- SNDX 1.8M
- Earning Date
- EVRI 08-06-2025
- SNDX 07-31-2025
- Dividend Yield
- EVRI N/A
- SNDX N/A
- EPS Growth
- EVRI N/A
- SNDX N/A
- EPS
- EVRI 0.16
- SNDX N/A
- Revenue
- EVRI $749,853,000.00
- SNDX $43,722,000.00
- Revenue This Year
- EVRI N/A
- SNDX $426.77
- Revenue Next Year
- EVRI $2.19
- SNDX $98.31
- P/E Ratio
- EVRI $88.95
- SNDX N/A
- Revenue Growth
- EVRI N/A
- SNDX N/A
- 52 Week Low
- EVRI $7.98
- SNDX $8.58
- 52 Week High
- EVRI $14.25
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- EVRI 0.92
- SNDX 38.70
- Support Level
- EVRI $14.19
- SNDX $8.74
- Resistance Level
- EVRI $14.25
- SNDX $9.56
- Average True Range (ATR)
- EVRI 0.03
- SNDX 0.54
- MACD
- EVRI -0.91
- SNDX -0.06
- Stochastic Oscillator
- EVRI 0.00
- SNDX 12.35
About EVRI Everi Holdings Inc.
Everi Holdings Inc provides entertainment and technology solutions for the casino, interactive, and gaming industry. It operates in two segments, namely Games and Financial Technology Solutions (FinTech). Enveri Games provides gaming operators with gaming technology products and services, which include gaming machines, slot machines, leased gaming equipment, and other products and services. Enveri FinTech provides gaming operators with financial technology products and services, which include services and equipment that facilitate casino patrons to access cash at gaming facilities through automated teller machines, point of sale debit card purchases, and others.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.